Sugi Predict

Sugi Predict / Compounds / SCHEMBL229622

SCHEMBL229622

SCHEMBL229622

O=[N+]([O-])c1cc2c(cc1Br)OCO2

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.62
▸ MEN1 O00255 4/20 0.62
▸ KMT2A Q03164 4/20 0.62
▸ POLB P06746 4/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.62
▸ MCL1 Q07820 1/20 0.62
▸ TXNRD1 Q16881 1/20 0.54
▸ TXNRD3 Q86VQ6 1/20 0.54
▸ TXNRD2 Q9NNW7 1/20 0.54
▸ SRC P12931 1/20 0.51
▸ ALDH1A1 P00352 10/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ GAA P10253 2/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519630 0.89 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL718255 0.86 MAPT (0.74) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL9471765 0.78 MAPT (0.65) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL9471773 0.78 MAPT (0.65) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL4126863 0.77 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL20505550 0.77 MAPT (0.68) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL608096 0.77 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL789918 0.77 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL123842 0.77 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL6361570 0.77 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 — — US disclosed
US-20220112206-A1 HETEROCYCLIC LSF INHIBITORS AND THEIR USES TRUSTEES OF BOSTON UNIVERSITY (US) 2022-04-14 — — US disclosed
US-11242353-B2 Heterocyclic LSF inhibitors and their uses TRUSTEES OF BOSTON UNIVERSITY (US) 2022-02-08 — — US disclosed
US-20210230173-A1 HETEROCYCLIC LSF INHIBITORS AND THEIR USES TRUSTEES OF BOSTON UNIVERSITY (US) 2021-07-29 — — US disclosed
WO-2021150835-A1 HETEROCYCLIC LSF INHIBITORS AND THEIR USES TRUSTEES OF BOSTON UNIVERSITY (US) 2021-07-29 — — WO disclosed
EP-1577288-B1 Selective estrogen receptor modulators EISAI R&D MAN CO LTD (JP) 2014-07-23 — — EP disclosed
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 — — US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 — — US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 — — US disclosed
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2010-02-04 — — US disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 — — US disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 — — US disclosed
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-18 — — US disclosed
WO-2008056150-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-I ANTAGONISTIC ACTIVITY ASTRAZENECA AB (SE) 2008-05-15 — — WO disclosed
EP-1892238-A1 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-02-27 — — EP disclosed
EP-1892238-A1 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-02-27 — — EP disclosed
US-20060281747-A1 1,2-di(cyclic) substituted benzene derivatives EISAI R&D MANAGEMENT CO., LTD. 2006-12-14 — — US disclosed
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-12-07 — — US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 — — US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11242353-B2 Heterocyclic LSF inhibitors and their uses PCLAF, FLI1, GTF2F1 MAPT 4042/4885MEN1 690/4885KMT2A 2008/4885
US-20090156589-A1 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE CCR10, H1-10, VCAM1 MAPT 4564/4885MEN1 2838/4885KMT2A 3548/4885
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 MAPT 4855/4885MEN1 4620/4885KMT2A 3843/4885
US-20060281747-A1 1,2-di(cyclic) substituted benzene derivatives CCR10, H1-10, CXCL10 MAPT 4459/4885MEN1 2708/4885KMT2A 3644/4885
US-20100029643-A1 HETEROCYCLYC SULFONAMIDES HAVING EDG-1 ANTAGONISTIC ACTIVITY EDF1, ERLIN1, ECE1 MAPT 4806/4885MEN1 423/4885KMT2A 2667/4885
US-20210230173-A1 HETEROCYCLIC LSF INHIBITORS AND THEIR USES PCLAF, FLI1, GTF2F1 MAPT 4042/4885MEN1 690/4885KMT2A 2008/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 MAPT 2593/4885MEN1 231/4885KMT2A 216/4885
US-20220112206-A1 HETEROCYCLIC LSF INHIBITORS AND THEIR USES PCLAF, FLI1, GTF2F1 MAPT 4042/4885MEN1 690/4885KMT2A 2008/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 MAPT 3856/4885MEN1 2539/4885KMT2A 455/4885
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds HRH3, CCR10, HRH1 MAPT 2706/4885MEN1 2159/4885KMT2A 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.